Sonographic monitoring of ovarian volume during LHRH analogue therapy in women with polycystic ovarian syndrome

J Ultrasound Med. 1988 Apr;7(4):203-6. doi: 10.7863/jum.1988.7.4.203.

Abstract

Polycystic ovarian disease is characterized by menstrual disorders, infertility, obesity, and large ovaries. Large ovaries with multiple cysts are the direct cause of the high incidence of ovarian hyperstimulation during ovulation induction. Lately, gonadotropin-releasing hormone (GnRH) analogues have been employed to decrease ovarian steroidogenesis and thus reduce the incidence of ovarian hyperstimulation. In this study the ovarian size was ultrasonographically assessed during chronic GnRH analogue treatment, revealing a significant reduction in ovarian volume. This decrease in volume results in a reduced incidence of hyperstimulation, and we think the ultrasonic scanning can be effectively used to assess the success of GnRH treatment.

MeSH terms

  • Female
  • Gonadotropin-Releasing Hormone / analogs & derivatives*
  • Gonadotropin-Releasing Hormone / therapeutic use
  • Humans
  • Luteolytic Agents / therapeutic use*
  • Ovary / pathology*
  • Polycystic Ovary Syndrome / drug therapy
  • Polycystic Ovary Syndrome / pathology*
  • Triptorelin Pamoate
  • Ultrasonography*

Substances

  • Luteolytic Agents
  • Triptorelin Pamoate
  • Gonadotropin-Releasing Hormone